Skip to content

DD Pharma

Active
Private limited companyfounded 2024active for 2 yearsTervuursesteenweg 333, 3001 Leuven, BelgiumKBO/BCE: BE 1014.418.872
Summary

The computed 12-month bankruptcy probability of DD Pharma is 1.5% (moderate). The 2025 annual accounts show equity of €11,524 and a net result of €8,524. Its solvency ranks better than 34% of 22,632 sector peers (NACE 47, financial year 2025). The company has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals.

Financials · financial year 2025, micro format

2025 annual accounts filed late (26 days) Filed on 26 May 2026, deadline 30 April 2026 (7 months after the close on 30 September 2025, Companies Code art. 3:10). Source: NBB, 2026-00126904.

Turnover
≈ €250,000
Estimated: probably between €88,000 and €510,000
Total assets
€75,776
Net result
€8,524
Working capital
-€10,807

Turnover and EBIT margin not published: the micro format does not require them. The turnover shown is an estimate from the gross margin.

Balance-sheet composition
Assets €75,776
Fixed assets €45,887
Current assets €29,889
Equity and liabilities €75,776
Equity €11,524
Debt €64,253
Debt finances 84.8% of the balance-sheet total.
Key figures and ratios
2025 value
EBITDA
€22,874
Cash flow
€21,432
Current ratio
0.73
Debt to equity
5.58
ROE
74.0%
ROA
11.2%
Interest coverage
15.86
Debt ≤ 1 year
€40,696
Debt > 1 year
€23,556

Peer companies

Historical observation

Of the 7,976 companies that looked in July 2024 the way this one looks now, 3.6% went bankrupt within 24 months and 94.4% are still going.

  • Micro
  • 2 to 5 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more
3.6% went bankrupt
1.8% stopped otherwise
94.4% still going

A further 0.3% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 1.5% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 7,976 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 37 lines
Balance sheet Code2025
Assets
Total assets20/58€75,776
Fixed assets21/28€45,887
Intangible fixed assets21€2,000
Tangible fixed assets22/27€43,887
Plant, machinery and equipment23€1,999
Furniture and vehicles24€41,888
Current assets29/58€29,889
Amounts receivable within one year40/41€8,690
Trade receivables40€8,210
Other amounts receivable41€480
Cash at bank and in hand54/58€21,199
Equity and liabilities
Total equity and liabilities10/49€75,776
Equity10/15€11,524
Contributions10/11€3,000
Profit (loss) carried forward14€8,524
Amounts payable17/49€64,253
Amounts payable after more than one year17€23,556
Financial debts170/4€23,556
Amounts payable within one year42/48€40,696
Current portion of amounts payable after more than one year42€9,810
Trade debts44€6,318
Suppliers440/4€6,318
Taxes, remuneration and social security45€11,262
Taxes450/3€11,262
Other amounts payable47/48€13,307
Income statement Code2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€12,908
Other operating charges640/8€125
Gross operating margin9900€22,999
Operating profit (loss)9901€9,966
Financial income75/76B€0
Recurring financial income75€0
Financial charges65/66B€1,442
Recurring financial charges65€1,442
Profit (loss) for the period before taxes9903€8,524
Profit (loss) for the period9904€8,524
Profit (loss) for the period to be appropriated9905€8,524
Appropriation of the result
Profit (loss) to be appropriated9906€8,524

The notes to these accounts (19 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€12,908
Other operating charges640/8€125
Gross operating margin9900€22,999
Operating profit (loss)9901€9,966
Financial income75/76B€0
Recurring financial income75€0
Financial charges65/66B€1,442
Recurring financial charges65€1,442
Profit (loss) for the period before taxes9903€8,524
Profit (loss) for the period9904€8,524
Profit (loss) for the period to be appropriated9905€8,524
Line2025
Assets
Total assets20/58€75,776
Fixed assets21/28€45,887
Intangible fixed assets21€2,000
Tangible fixed assets22/27€43,887
Plant, machinery and equipment23€1,999
Furniture and vehicles24€41,888
Current assets29/58€29,889
Amounts receivable within one year40/41€8,690
Trade receivables40€8,210
Other amounts receivable41€480
Cash at bank and in hand54/58€21,199
Equity and liabilities
Total equity and liabilities10/49€75,776
Equity10/15€11,524
Contributions10/11€3,000
Profit (loss) carried forward14€8,524
Amounts payable17/49€64,253
Amounts payable after more than one year17€23,556
Financial debts170/4€23,556
Amounts payable within one year42/48€40,696
Current portion of amounts payable after more than one year42€9,810
Trade debts44€6,318
Suppliers440/4€6,318
Taxes, remuneration and social security45€11,262
Taxes450/3€11,262
Other amounts payable47/48€13,307
Line2025
Profit (loss) for the period9904€8,524
+ Depreciation and write-downs630€12,908
Operating cash flow (approximation)€21,432

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (1)
Financial year Type Filed Reference
30-09-2025 micro format 26-05-2026 2026-00126904

Similar companies · same sector, comparable size

Of the 5,204 active companies whose main activity is retail sale of pharmaceutical products (NACE 47730), figures are known for 3,902. 970 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.